Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1897 1
1898 1
1905 1
1907 1
1915 1
1922 1
1925 3
1926 1
1928 2
1929 2
1930 3
1931 3
1932 2
1933 1
1934 3
1935 3
1936 2
1938 2
1939 2
1940 3
1941 2
1942 1
1943 4
1944 2
1945 7
1946 25
1947 20
1948 16
1949 21
1950 28
1951 26
1952 43
1953 40
1954 83
1955 43
1956 74
1957 56
1958 70
1959 37
1960 80
1961 97
1962 100
1963 179
1964 240
1965 226
1966 347
1967 435
1968 457
1969 506
1970 508
1971 601
1972 563
1973 509
1974 413
1975 454
1976 427
1977 435
1978 487
1979 559
1980 684
1981 705
1982 842
1983 1011
1984 1281
1985 1554
1986 1792
1987 2250
1988 2489
1989 3020
1990 3555
1991 3791
1992 3957
1993 4141
1994 4803
1995 5179
1996 5484
1997 5851
1998 5892
1999 6358
2000 7288
2001 7636
2002 8124
2003 8876
2004 9610
2005 10292
2006 10521
2007 10543
2008 11133
2009 11491
2010 12070
2011 13155
2012 13577
2013 14083
2014 14651
2015 14901
2016 15382
2017 15843
2018 16474
2019 16929
2020 18710
2021 20841
2022 21300
2023 19909
2024 20950
2025 24320
2026 18788
2027 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426,687 results

Results by year

Filters applied: . Clear all
Page 1
Developing the next-generation of adenoviral vector vaccines.
Sampson AT, Hlaváč M, Gillman ACT, Douradinha B, Gilbert SC. Sampson AT, et al. Hum Vaccin Immunother. 2025 Dec;21(1):2514356. doi: 10.1080/21645515.2025.2514356. Epub 2025 Jul 1. Hum Vaccin Immunother. 2025. PMID: 40590260 Free PMC article. Review.
The COVID-19 pandemic saw the first extensive use of adenoviral vector vaccines, with over 3 billion doses produced during the first year of the pandemic alone and an estimated 6 million lives saved. ...Despite their successful deployment against SARS-CoV-2, their impact h …
The COVID-19 pandemic saw the first extensive use of adenoviral vector vaccines, with over 3 billion doses produced during the first …
Vector-based genetically modified vaccines: Exploiting Jenner's legacy.
Ramezanpour B, Haan I, Osterhaus A, Claassen E. Ramezanpour B, et al. Vaccine. 2016 Dec 7;34(50):6436-6448. doi: 10.1016/j.vaccine.2016.06.059. Epub 2016 Oct 28. Vaccine. 2016. PMID: 28029542 Free PMC article. Review.
Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study further highlights that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. After the approva …
Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study …
Adenovirus vector production and purification.
Silva AC, Peixoto C, Lucas T, Küppers C, Cruz PE, Alves PM, Kochanek S. Silva AC, et al. Curr Gene Ther. 2010 Dec;10(6):437-55. doi: 10.2174/156652310793797694. Curr Gene Ther. 2010. PMID: 21054247 Review.
Replication deficient adenovirus vectors are frequently used tools for the delivery of transgenes in vitro and in vivo. In addition, several therapeutic products based on adenovirus are under clinical development. This review outlines adenovirus vector production di …
Replication deficient adenovirus vectors are frequently used tools for the delivery of transgenes in vitro and in vivo. In addition, …
The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine.
Sallard E, Zhang W, Aydin M, Schröer K, Ehrhardt A. Sallard E, et al. Viruses. 2023 Jan 11;15(1):204. doi: 10.3390/v15010204. Viruses. 2023. PMID: 36680244 Free PMC article. Review.
Over recent years, the adenovirus vector platform has been in the center of attention for vaccine development against the ongoing coronavirus SARS-CoV-2/COVID-19 pandemic. ...This review covers the full spectrum of state-of-the-art strategies to avoid vector-induced …
Over recent years, the adenovirus vector platform has been in the center of attention for vaccine development against the ongoing cor …
Viral vector-based influenza vaccines.
de Vries RD, Rimmelzwaan GF. de Vries RD, et al. Hum Vaccin Immunother. 2016 Nov;12(11):2881-2901. doi: 10.1080/21645515.2016.1210729. Epub 2016 Jul 25. Hum Vaccin Immunother. 2016. PMID: 27455345 Free PMC article.
The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, o …
The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet ne …
Managing microRNAs with vector-encoded decoy-type inhibitors.
Bak RO, Hollensen AK, Mikkelsen JG. Bak RO, et al. Mol Ther. 2013 Aug;21(8):1478-85. doi: 10.1038/mt.2013.113. Epub 2013 Jun 11. Mol Ther. 2013. PMID: 23752312 Free PMC article. Review.
Here, we provide an overview of the strategies that have been used to adapt vector-encoded inhibitors for miRNA suppression and discuss advantages related to spatiotemporal and long-term miRNA attenuation. ...The community will aspire to combine circles with high-affinity …
Here, we provide an overview of the strategies that have been used to adapt vector-encoded inhibitors for miRNA suppression and discu …
Adenoviral vector immunity: its implications and circumvention strategies.
Ahi YS, Bangari DS, Mittal SK. Ahi YS, et al. Curr Gene Ther. 2011 Aug;11(4):307-20. doi: 10.2174/156652311796150372. Curr Gene Ther. 2011. PMID: 21453277 Free PMC article. Review.
However, the presence of preexisting Ad immunity and the rapid development of Ad vector immunity still pose significant challenges to the clinical use of these vectors. ...This review provides an update on our current understanding of immune responses to Ad vecto …
However, the presence of preexisting Ad immunity and the rapid development of Ad vector immunity still pose significant challenges to …
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.
Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X. Wang S, et al. Signal Transduct Target Ther. 2023 Apr 7;8(1):149. doi: 10.1038/s41392-023-01408-5. Signal Transduct Target Ther. 2023. PMID: 37029123 Free PMC article. Review.
Currently, viral vector vaccines remain one of the best strategies for induction of robust humoral and cellular immunity against human diseases. ...This review summarized the overall profile of the design strategies, progress in advance and steps taken to address barriers …
Currently, viral vector vaccines remain one of the best strategies for induction of robust humoral and cellular immunity against huma …
On the Choice of the Right Plasmid Vector(s) in the Times of Synthetic Biology.
de Lorenzo V, Martínez-García E. de Lorenzo V, et al. Microb Biotechnol. 2025 Dec;18(12):e70273. doi: 10.1111/1751-7915.70273. Microb Biotechnol. 2025. PMID: 41395802 Free PMC article. Review.
Plasmid vectors are to this day the fundamental tools in molecular biology, but their selection is often guided by convenience rather than informed choice. ...The growing need for reliable, portable vectors has driven the development of broad-host-range backbones, s …
Plasmid vectors are to this day the fundamental tools in molecular biology, but their selection is often guided by convenience rather …
Integrase deficient lentiviral vector: prospects for safe clinical applications.
Yew CT, Gurumoorthy N, Nordin F, Tye GJ, Wan Kamarul Zaman WS, Tan JJ, Ng MH. Yew CT, et al. PeerJ. 2022 Aug 12;10:e13704. doi: 10.7717/peerj.13704. eCollection 2022. PeerJ. 2022. PMID: 35979475 Free PMC article.
HIV-1 derived lentiviral vector is an efficient transporter for delivering desired genetic materials into the targeted cells among many viral vectors. ...Various measures have been administered in different generations of lentiviral vector systems to r …
HIV-1 derived lentiviral vector is an efficient transporter for delivering desired genetic materials into the targeted cells a …
426,687 results
You have reached the last available page of results. Please see the User Guide for more information.